Cas:591735-92-1 N-methyl-2-nitro-5-piperidin-1-ylaniline manufacturer & supplier

Chemical Name:N-methyl-2-nitro-5-piperidin-1-ylaniline

CAS.NO:591735-92-1

Synonyms:N-methyl-2-nitro-5-(piperidin-1-yl)aniline

Molecular Formula:C₁₂H₁₇N₃O₂

Molecular Weight:235.28200

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:61.09000

Exact Mass:235.13200

LogP:3.28800

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-methyl-2-nitro-5-(piperidin-1-yl)aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-methyl-2-nitro-5-(piperidin-1-yl)aniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-methyl-2-nitro-5-(piperidin-1-yl)aniline Use and application,N-methyl-2-nitro-5-(piperidin-1-yl)aniline technical grade,usp/ep/jp grade.

Related News: With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow. N-methyl-2-nitro-5-piperidin-1-ylaniline manufacturer China has granted conditional approval to its first self-developed treatment for Alzheimer��s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug. N-methyl-2-nitro-5-piperidin-1-ylaniline supplier There are however certain APIs that are unknown and so require additional substances that work in conjunction with the API to produce the required effect. N-methyl-2-nitro-5-piperidin-1-ylaniline vendor Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. N-methyl-2-nitro-5-piperidin-1-ylaniline factory There are however certain APIs that are unknown and so require additional substances that work in conjunction with the API to produce the required effect.